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Background
The aim was to determine the dynamic of clinical symp-
toms and saliva concentrations (SC) of IL-4, IL-13, IFNg
in children (Ch) with atopic dermatitis (AD) in the set-
ting of background therapy (BT) and accelerated parent-
eral allergen-specific immunotherapy (APAI) with house
dust mite allergens (HDMA).
Methods
The study included a total of 33 Ch with non-acute AD.
The mean age at enrollment was 7.2±2.1. The APAI has
been provided for 36 months (M) according to accelerated
regimen by parenteral introduction of HDMA (2 times/
daythrough 6 h.), along with BT. SC of IL-4, IL-13, IFNg
were measured using ELISA at 1, 3, 6, 12 and 36M after
treatment initiation.
Results
The efficacy after 12M of APAI was 78.7–84.8% depend-
ing on disease severity. The “excellent” result after APAI
course was achieved in 21.2% Ch with AD, “good” in
57.6% Ch, “satisfactory” in 9.1% Ch, and there was no
therapeutic effect in 12.1% Ch. There was reduction in
the number, duration and severity of AD exacerbations
observed in 2/3 Ch, which allowed the subsequent reduc-
tion of BT. As early as at 6 M there was a 1.5 times
decrease of hospitalization number (p<0.05) as compared
to the pre-treatment year. After the 1st M of APAI in Ch
with AD there was no significant decrease of SC of IL-4,
IL-13 and no increase of saliva IFNg level either (p<0.05).
There was no normalization of SC IL-4 and IL-13 during
first 6 months in Ch with severe AD as well, though their
levels decreased at an average of more than 1.5 times.
12 M of APAI provided duplication of local SC of IFNg.
This saliva IFNg increase in Ch with AD on the back-
ground of APAI was accompanied by decrease of specific
IgE againstHDMA (r= –0.73). The pre-APAI immune
disorder formula was IL-43+IL-132+IFNg3-IgE3+. After
termination of treatment course withHDMA it has chan-
ged for IL-42+IL-132+IFNg1-IgE2+.
Conclusions
The results showed that pathogenetic therapy contri-
butes to reduction of SC and inhibits immune inflam-
mation by down regulating the pro-inflammatory
cytokine IL-4 and IL-13 production and activating IFNg
synthesis. Thus the accelerated parenteral APAI is effec-
tive in Ch with AD.
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